isopropyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate | 329222-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: isopropyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
• 英文别名: 2-Amino-6-methyl-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid isopropyl ester；propan-2-yl 2-amino-6-methyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate
• CAS: 329222-97-1
• 化学式: C₁₃H₁₉NO₂S
• mdl: MFCD00783380
• 分子量: 253.365
• InChiKey: PMEGAOJOWAZQLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.615
• 拓扑面积：
  80.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  isopropyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 25.0h， 生成 isopropyl 2-(2-(2-imino-4-oxothiazolidin-5-yl)acetamido)-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
  参考文献：
  名称：

  An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups

  摘要：

  N-甲基-d-天冬氨酸受体（NMDAR）是大脑中的一种重要受体，与多种神经系统疾病有关。许多非选择性 NMDAR 靶向药物的耐受性都很差，因此人们努力靶向 NMDAR 亚型以提高治疗指数。我们在此介绍了一系列在饱和浓度下具有亚最大抑制作用的负异构 NMDAR 调节剂。化学结构的适度变化可将负调制与正调制相互转换。所有调节剂都具有增强激动剂效力的能力，并且具有使用依赖性，在调节剂发挥高效力之前需要同时与两种激动剂结合。数据表明，这些调节剂（包括两种对映体）与受体上的相同位点结合，并具有共同的作用结构决定因素。由于调制剂的特性，该系列中的亚最大负性调制剂可能会使突触处的 NMDAR 免受影响，同时增强 NMDAR 在突触外空间的反应。这些调节剂可作为探究突触外 NMDAR 作用的有用工具。

  DOI：

  10.7554/elife.34711
• 作为产物：
  描述：

  氰乙酸异丙酯 、 4-甲基环己酮 在 吗啉 、 sulfur 作用下， 以 异丙醇 为溶剂， 以98%的产率得到isopropyl 2-amino-6-methyl-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate
  参考文献：
  名称：

  An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups

  摘要：

  N-甲基-d-天冬氨酸受体（NMDAR）是大脑中的一种重要受体，与多种神经系统疾病有关。许多非选择性 NMDAR 靶向药物的耐受性都很差，因此人们努力靶向 NMDAR 亚型以提高治疗指数。我们在此介绍了一系列在饱和浓度下具有亚最大抑制作用的负异构 NMDAR 调节剂。化学结构的适度变化可将负调制与正调制相互转换。所有调节剂都具有增强激动剂效力的能力，并且具有使用依赖性，在调节剂发挥高效力之前需要同时与两种激动剂结合。数据表明，这些调节剂（包括两种对映体）与受体上的相同位点结合，并具有共同的作用结构决定因素。由于调制剂的特性，该系列中的亚最大负性调制剂可能会使突触处的 NMDAR 免受影响，同时增强 NMDAR 在突触外空间的反应。这些调节剂可作为探究突触外 NMDAR 作用的有用工具。

  DOI：

  10.7554/elife.34711

文献信息

• Design, Synthesis, and Structure–Activity Relationship of <i>N</i>-Aryl-<i>N</i>′-(thiophen-2-yl)thiourea Derivatives as Novel and Specific Human TLR1/2 Agonists for Potential Cancer Immunotherapy
  作者：Zhipeng Chen、Lina Zhang、Junjie Yang、Lu Zheng、Fanjie Hu、Siqin Duan、Kutty Selva Nandakumar、Shuwen Liu、Hang Yin、Kui Cheng

  DOI：10.1021/acs.jmedchem.0c02266

  日期：2021.6.10

  cells. To the best of our knowledge, it is the first species-specific TLR1/2 agonist reported until now. Moreover, SMU-C80 increased the percentage of T, B, and NK cells ex vivo and activated the immune cells, which suppressed cancer cell growth in vitro. In summary, we obtained a highly efficient and specific human TLR1/2 agonist that acts through the MyD88 and NF-κB pathway, facilitating cytokine release

  之前对 1000 万种化合物的虚拟筛选产生了两种新的非脂肽样化学型作为 TLR2 激动剂。在此，我们介绍了我们最初命中的 1-苯基-3-(噻吩-2-基) 脲的化学优化，这导致将 SMU-C80 (EC 50 = 31.02 ± 1.01 nM)鉴定为 TLR2 特异性生物活性提高 370 倍的激动剂。机理研究表明，SMU-C80 通过 TLR1/2 募集接头蛋白 MyD88 并触发 NF-κB 通路以从人类而非鼠类细胞中释放细胞因子，例如 TNF-α 和 IL-1β。据我们所知，它是迄今为止报道的第一个物种特异性 TLR1/2 激动剂。此外，SMU-C80 增加了离体T、B 和 NK 细胞的百分比并激活免疫细胞，从而抑制体外癌细胞的生长。总之，我们获得了一种高效且特异的人 TLR1/2 激动剂，它通过 MyD88 和 NF-κB 途径起作用，促进细胞因子的释放和免疫细胞的同时激活，进而影响癌细胞的凋亡。
• Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor
  申请人：——

  公开号：US20040171603A1

  公开（公告）日：2004-09-02

  Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Additionally disclosed are novel 4,5,6,7-tetrahydrobenzo[b]thiophene compounds, benzo(g)quinoxaline compounds, and pharmaceutically acceptable salts thereof, and methods of using such compounds and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo(g)quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.

  本文描述的是发现某些分枝杆菌丝氨酸/苏氨酸蛋白激酶，特别是蛋白激酶 G (PknG)，是治疗分枝杆菌感染的有效治疗靶点。此外，本申请还涉及利用分枝杆菌丝氨酸/苏氨酸蛋白激酶开发检测和测定这些激酶的方法，用于识别和监测疾病以及控制疾病的治疗。此外，还公开了新型 4,5,6,7-四氢苯并[b]噻吩化合物、苯并（g）喹喔啉化合物及其药学上可接受的盐，以及使用此类化合物及其盐预防和/或治疗病毒和/或细菌引起的感染，特别是分枝杆菌引起的感染（包括机会性感染）的方法，以及含有至少一种 4,5,6,7-四氢苯并&lsqb；b]噻吩化合物和/或苯并(g)喹喔啉化合物和/或其药学上可接受的盐，并将其置于药学上可接受的载体中。
• Structure-Based Virtual Screening, Compound Synthesis, and Bioassay for the Design of Chitinase Inhibitors
  作者：Yawen Dong、Xi Jiang、Tian Liu、Yun Ling、Qing Yang、Li Zhang、Xiongkui He

  DOI：10.1021/acs.jafc.8b00017

  日期：2018.4.4

  Chitinases play a vital part in the molting phase of insect pests. Inhibiting their activities by the use of drug-like small chemical molecules is thought to be an efficient strategy in pesticide design and development. On the basis of the crystal structure of Of ChtI, a chitinase indispensable for the molting of the insect pest Ostrinia furnacalis (Asian corn borer), here we report a chemical fragment and five variant compounds as inhibitors of Of ChtI obtained from a library of over 200 000 chemicals by a structure-based-virtual-screening approach. The compounds were synthesized with high atom economy and tested for their. Of ChtI-inhibitory activities in a bioassay. Compound 3 showed preferential inhibitory activity with a K-i value of 1.5 mu M against Of ChtI. Analysis of the structure-activity relationships of the compounds provided insight into their interactions with the enzyme active site, which may inform future work in improving the potencies of their inhibitory activities.
• 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections
  申请人：Missio Andrea

  公开号：US20090018149A1

  公开（公告）日：2009-01-15

  Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases.